Novartis (NVS) Signs $7.8 Billion Deal with Chinese Biotech Abogen

Novartis (NVS) has entered a licensing agreement with China-based Abogen Biosciences valued at up to $7.8 billion. The deal includes an upfront payment of $575 million for global rights to a messenger RNA therapy, plus $7.2 billion in potential milestone payments. This move comes amid concerns over Novartis' ability to develop new drugs as patents on top-selling products approach expiration in the early 2030s. This agreement illustrates the increasing trend of Western pharmaceutical companies seeking innovative drug solutions from China's biotech sector, which is expected to account for a significant portion of new drug development going forward.